Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.
To study characteristics, treatment approaches and outcome of HIV-infected patients with malignant lymphoma in the combination antiretroviral therapy (cART) era. HIV-infected persons diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma will be included. The choice of treatment is not specified by the registry study. However, the type of antineoplastic treatment should follow national or international recommendations and guidelines. Data will be pseudonymized by the data manager of the treating institution. Central data management is located at Red Cross Hospital Munich, Germany.
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| 2-year overall survival (OS) | OS measured from the date of diagnosis to last follow-up or to death from any cause. | 2 years |
| 2-year progression-free survival (PFS) | PFS calculated from the date of diagnosis to the time of progression, relapse, or death. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of relapse (IR) | Based on establised response criteria, e.g. Chesson et al. JCO 2014 | 5 years |
| Non-relapse mortality (NRM) | Deaths unrelated to lymphoma |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Unselected cohort of adults with HIV-lymphoma
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marcus Hentrich, MD | Contact | +49 89 1303 4372 | marcus.hentrich@swmbrk.de | |
| Kai Hübel, MD | Contact | +49 221 478 86177 | kai.huebel@uk-koeln.de |
| Name | Affiliation | Role |
|---|---|---|
| Marcus Hentrich, MD | Rotkreuzklinikum München | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Red Cross Hospital Munich | Recruiting | Munich | Select One Option | 80634 | Germany |
Not provided
| ID | Term |
|---|---|
| D016483 | Lymphoma, AIDS-Related |
| D008223 | Lymphoma |
| ID | Term |
|---|---|
| D016393 | Lymphoma, B-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 years |
| 5-year overall survival (OS) | OS measured from the date of diagnosis to last follow-up or to death from any cause. | 5 years |
| 5-year progression-free survival (PFS) | PFS calculated from the date of diagnosis to the time of progression, relapse, or death. | 5 years |
| University Hospital Cologne | Recruiting | Cologne | 50937 | Germany |
|
| Amsterdam University Medical Centers | Not yet recruiting | Amsterdam | Netherlands |
|
| Hospital de la Santa Creu i Sant Pau | Recruiting | Barcelona | Spain |
|
| Hospital Universitario de Salamanca | Recruiting | Salamanca | Spain |
|
| University Hospital of Wales | Not yet recruiting | Cardiff | United Kingdom |
|
| D008232 |
| Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |